Methods are being developed and applied for more objectively determining and quantifying abnormalities of extent and timing of regional ventricular wall motion from cineventriculograms. Using one method of analysis, normal values have been established and are being used as a basis for detecting and quantifying the severity of segmental wall motion abnormalities. Studies will be done to determine the extent to which the human left ventricle can compensate for regional function abnormalities and maintain global function as determined by the ejection fraction and the early systolic rate of ejection and early partial systolic ejection fraction. It will be determined if measures of regional function can provide earlier evidence of deteriorating LV performance than measures of global function such as ejection fraction in patients with aortic and/or mitral valve insufficiency. The influence of delayed regional contraction and relaxation on the peak negative dp/dt in diastole will be studied. In other studies a new technique for quantifying coronary artery dimensions and extent of stenosis from coronary arteriograms will be further evaluated and applied to determine vasomobility of coronary arteries and stenotic coronary artery lesions to a variety of cardiac drugs and reflexes such as hand grip and immersion of a hand in ice water. The quantified coronary artery stenosis will be related to coronary insufficiency syndromes and wall motion abnormalities. Finally, studies are and will be done to further define the natural history of coronary artery lesions and the effect of therapeutic interventions (initially aspirin and dipyridamole) on the course of lesions. These latter studies may lead to more effective measures to prevent the development and progression of coronary stenoses due to atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL019451-10
Application #
3335846
Study Section
Cardiovascular and Pulmonary Research B Study Section (CVB)
Project Start
1976-05-01
Project End
1986-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
10
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Zambon, Alberto; Zhao, Xue-Qiao; Brown, B Greg et al. (2014) Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 113:1494-8
Phan, Binh An P; Moore, Andrew B; Davis, Joseph et al. (2014) Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol 8:489-93
Zhao, Xue-Qiao; Krasuski, Richard A; Baer, Jefferson et al. (2009) Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclero Am J Cardiol 104:1457-64
Zhao, X Q; Yuan, C; Hatsukami, T S et al. (2001) Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21:1623-9
Hosokawa, H; Sheehan, F H; Suzuki, T (2000) Measurement of postsystolic shortening to assess viability and predict recovery of left ventricular function after acute myocardial infarction. J Am Coll Cardiol 35:1842-9
Brown, B G (1999) Assessment for subclinical ischemia: bridging the gap between primary and secondary prevention. Am J Med 107:28S-30S
Zambon, A; Hokanson, J E; Brown, B G et al. (1999) Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959-64
Brown, B G; Zambon, A; Poulin, D et al. (1998) Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 81:52B-59B
Brown, B G; Bardsley, J; Poulin, D et al. (1997) Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 80:111-5
Brown, B G; Zhao, X Q; Bardsley, J et al. (1997) Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. J Intern Med 241:283-94

Showing the most recent 10 out of 50 publications